Molecular action of methotrexate in inflammatory diseases

@article{Chan2002MolecularAO,
  title={Molecular action of methotrexate in inflammatory diseases},
  author={Edwin S. L. Chan and Bruce N. Cronstein},
  journal={Arthritis Research},
  year={2002},
  volume={4},
  pages={266 - 273}
}
Despite the recent introduction of biological response modifiers and potent new small-molecule antirheumatic drugs, the efficacy of methotrexate is nearly unsurpassed in the treatment of inflammatory arthritis. Although methotrexate was first introduced as an antiproliferative agent that inhibits the synthesis of purines and pyrimidines for the therapy of malignancies, it is now clear that many of the anti-inflammatory effects of methotrexate are mediated by adenosine. This nucleoside, acting… Expand
Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis.
TLDR
The latest developments in the pharmacokinetics, mechanism of action, pharmacogenetics, and toxicity of methotrexate are herein discussed. Expand
Methotrexate in dermatology
TLDR
This review of methotrexate's pharmacokinetics, mode of administration, dosing guidelines, side effect profile, and medication interactions will offer practical guidelines for dose initiation and adjustment, and summarize new research on its mechanism of action and implications for future therapy. Expand
Methotrexate for psoriasis in the era of biological therapy
TLDR
The potential for personalized methotrexate use by application of modern pharmacogenetics and pharmacokinetics may ensure its place as a first‐line agent for the treatment of psoriasis for the foreseeable future. Expand
4.Methotrexate(MTX)
TLDR
MTX pharmacogenetics that was related to a large interindividual variation on efficacy and adverse drug reactions in RA patients are described, including MTX transporter Pharmacogenetics, MTX glutamation pharmacogenetic, folate pathway pharmacogenetically, and adenosine pathway pharmacogenicetics. Expand
Molecular mechanism of action and pharmacokinetic properties of methotrexate
TLDR
Authors are conducting research on oral methotrexate use and pharmacokinetics in chronic sarcoidosis patients and have performed literature research to better understand molecular mechanisms of metotrexate action as well as high level pharmacokinetic considerations. Expand
Pharmacogenetics of methotrexate.
TLDR
Several genetic variants have been shown to have a predictive role, among which the most frequently studied are those of methylenetetrahydrofolate reductase and thymidylate synthase genes. Expand
The pharmacogenetics of methotrexate.
TLDR
This review critically appraises the studies of MTX pharmacogenetics and highlights the need for further work in this area. Expand
Pharmacogenetics: implications for therapy in rheumatic diseases
TLDR
The pharmacogenetic applications of commonly used DMARDs, methotrexate, and the newer, more expensive biologic agents might make personalized therapy in rheumatic diseases possible. Expand
Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.
TLDR
Key pharmacogenetic studies examining SNPs in the genes encoding enzymes in the MTX cellular pathway and their association with MTX response in RA are summarized. Expand
Pharmacogenomics in the treatment of rheumatoid arthritis: clinical implication and perspective.
TLDR
Investigations suggest that the pharmacogenomic approach is useful for the treatment of RA, although there are points to be considered before the translation of the Pharmacogenomic data into clinical practice. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 119 REFERENCES
Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.
TLDR
The data demonstrate that MTX can selectively delete activated peripheral blood T cells by a CD95-independent pathway, and this property could be used as a new pharmacological end point to optimize dosage and timing of MTX administration. Expand
Mechanism of Action of Methotrexate: Experimental Evidence that Methotrexate Blocks the Binding of Interleukin 1β to the Interleukin 1 Receptor on Target Cells
  • M. Brody, I. Böhm, R. Bauer
  • Biology, Medicine
  • European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies
  • 1993
TLDR
Methotrexate is another interleukin 1 inhibitor and a clinically efficient anticytokine and demonstrated that methotrexate does not affect the integrity of the interleucin 1 receptor or of the target cells. Expand
Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines.
TLDR
An individually adjusted supply of folic acid rather than folinic acid is proposed for supplementation during methotrexate therapy of patients with rheumatoid arthritis, addressing both the timing of folate supplementation and the weekly folate-to-methotrexate ratio. Expand
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.
TLDR
Results indicate that methotrexate is a nonsteroidal antiinflammatory agent, the antiphlogistic action of which is due to increased adenosine release at inflamed sites. Expand
Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis.
TLDR
Investigation of the effects of MTX on the gene expression and synthesis of interleukin-6, and the proliferative activity and the production of ROS in the fibroblast-like synoviocytes (FLSs) obtained from the patient of RA suggests inflammatory reaction in the synovium of RA patients could be augmented by the autocrine or other cytokine-induced production of IL-6. Expand
The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis.
TLDR
It is suggested that methotrexate may affect IL-1 production andIL-1 mediated events in some patients and this data indicates that this drug may be a potential new treatment option for rheumatoid arthritis. Expand
The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion.
TLDR
The ability to metabolize MTX to 7- OH-MTX and the sensitivity of AICARTase to inhibition by 7-OH- MTX may at least partially account for the variability in response to MTX. Expand
Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis
TLDR
The results suggest a cell-type specific effect of intravenously administered low-dose methotrexate on peripheral blood lymphocytes that may contribute to the mode of action of metotrexate as an immunosuppressive drug in the treatment of rheumatoid arthritis. Expand
The effects of methotrexate on the production and activity of interleukin-1.
TLDR
It is demonstrated that methotrexate is capable of inhibiting some IL-1 activities without affectingIL-1 production or secretion, and proposed that the inhibition of IL- 1 activity or IL-2-dependent events may be one of the mechanisms of action of MTX in RA. Expand
Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis.
TLDR
Folinic acid supplementation resulted in a significant reduction in the most common side effects of MTX, without affecting the clinical efficacy of the drug. Expand
...
1
2
3
4
5
...